Adenosine A3 Receptor Agonists for the Treatment of Neuropathic Pain
Abstract
Our goal is to develop BIO-205, a highly-selective agonist for the A3 adenosine receptor subtype, as an orally-administered monotherapy analgesic for the treatment of neuropathic pain and as an adjunct for opioid analgesics that increases analgesic efficacy while blocking the opioids unwanted effects (addiction potential, tolerance, and physical dependency). To reach this goal, the current grant supports drug manufacture, the development of analytic methods to measure the drug in biologic fluids, animal safety and toxicology studies, and the preparation of requisite documentation for an application to the FDA for an Investigational New Drug (IND) designation. In the past year we have successfully completed all tasks except for document preparatoin. Completion of documents (an Investigator Brochure and a plan for Phase 1 studies) are awaiting receipt of the toxicology Final Reports. These are expected prior to the end of 2020, which would put us on schedule for an FDA submission in Q1 of 2021.
Document Details
- Document Type
- Technical Report
- Publication Date
- Oct 01, 2020
- Accession Number
- AD1123369
Entities
People
- Gary J. Bennett